Login to Your Account



Venetoclax conditionally cleared by EMA in CLL; Ocaliva approved, too

By Nuala Moran
Staff Writer

Saturday, October 15, 2016

LONDON – The EMA has followed the FDA's lead and recommended conditional approval of Abbvie Inc.'s Venclexta (venetoclax) for treating chronic lymphocytic leukemia (CLL), on the basis of a single-arm pivotal phase II study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription